Get the Stockscreener App
66.96
6.03%
3.81
After Hours:
66.96
Tarsus Pharmaceuticals Inc stock is traded at $66.96, with a volume of 414.56K.
It is up +6.03% in the last 24 hours and down -7.83% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
See More
Previous Close:
$63.15
Open:
$64.35
24h Volume:
414.56K
Relative Volume:
0.69
Market Cap:
$2.85B
Revenue:
$451.36M
Net Income/Loss:
$-66.42M
P/E Ratio:
-41.60
EPS:
-1.6097
Net Cash Flow:
$-22.31M
1W Performance:
-1.88%
1M Performance:
-7.83%
6M Performance:
+20.89%
1Y Performance:
+30.45%
1-Day Range:
$64.35
$67.76
1-Week Range:
$61.51
$67.77
52-Week Range:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
66.96 | 2.69B | 451.36M | -66.42M | -22.31M | -1.6097 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Can Tarsus Pharmaceuticals Inc maintain sales growth2026 Setups & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - Yahoo Finance
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - The Motley Fool
Tarsus to receive $15M milestone after China approves TP-03 eye therapy - MSN
Tarsus earns $15M milestone on China approval of eye drug - Investing.com India
William Blair reiterates Outperform on Tarsus Pharmaceuticals stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals shares rise on China drug approval milestone By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (TARS) Reaches $15M Milestone After TP-03 Approval in China - GuruFocus
Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China - Quiver Quantitative
China clears first Demodex blepharitis treatment for 40 million people - Stock Titan
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Sahm
LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS) - The Globe and Mail
TARS SEC FilingsTarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(TARS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - MSN
Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $2,364,904, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals Insider Sold Shares Worth $892,528, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals Insider Sold Shares Worth $772,444, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharma Executives Quietly Unload a Wave of Shares in Coordinated Sell-Off - TipRanks
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 390 Shares - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 375 Shares - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Jeffrey Farrow Sells 2,111 Shares - MarketBeat
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,186 Shares of Stock - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 11,667 Shares - MarketBeat
Bobak Azamian Sells 10,972 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Dianne Whitfield Sells 4,071 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Bryan Wahl Sells 4,084 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharma CHRO Whitfield sells $839k in shares By Investing.com - Investing.com South Africa
Azamian, Tarsus Pharmaceuticals CEO, sells $2.36m in stock - Investing.com
Tarsus Pharma CMO Lin sells $78k in shares - Investing.com
Tarsus Pharma CMO Lin sells $78k in shares By Investing.com - Investing.com Australia
Azamian, Tarsus Pharmaceuticals CEO, sells $2.36m in stock By Investing.com - Investing.com Australia
Farrow Jeffrey S of Tarsus Pharma sells $439k in shares - Investing.com Australia
Tarsus Pharma COO Neervannan Seshadri sells $772k in shares - Investing.com
Tarsus Pharma general counsel Wahl sells $850k in stock - Investing.com
Tarsus Pharmaceuticals Insiders Sold Shares Worth Over $5.1M - TradingView
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan
Tarsus (NASDAQ: TARS) counsel sells shares to cover RSU tax - Stock Titan
Tarsus Pharmaceuticals (TARS) COO mandated sell-to-cover totals 11,324 shares - Stock Titan
Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan
Tarsus (NASDAQ: TARS) CMO sells shares to cover RSU tax withholding - Stock Titan
Tarsus (TARS) officer sells 6,430 shares in mandated tax sell-to-cover - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 34,603 shares to cover taxes - Stock Titan
TARS (NASDAQ: TARS) files notice to sell 2,186 shares via Fidelity - Stock Titan
TARS (NASDAQ: TARS) insider notifies sale of 4,440 shares via Fidelity - Stock Titan
TARS (NASDAQ: TARS) insider filings show proposed sale and recent dispositions - Stock Titan
Dianne Whitfield reports planned stock sales — TARS (NASDAQ: TARS) - Stock Titan
TARS (NASDAQ: TARS) insider sale notice; Bryan Wahl disposed of 8,209 shares - Stock Titan
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):